Bevacizumab (Avastin)

Bevacizumab (Avastin) is covered only for selected non‑oncology, compendia‑supported ophthalmologic indications (diabetic retinopathy, neovascular AMD, diabetic macular edema, macular edema from retinal vein occlusion, and macular choroidal neovascularization); oncology uses are excluded. Coverage requires an approved off‑label compendial indication with clinical documentation that the patient meets the specific coverage and safety criteria, and approvals are limited to up to 12 months.

"Diabetic Retinopathy"

Sign up to see full coverage criteria, indications, and limitations.